Redefining what's possible in genetic analysis
Introducing our work
Here at Depixus we are developing a platform for analysing the genomics of biological systems at new levels of resolution.
Our MAGNATM technology goes beyond decoding the static genetic code to reveal the dynamics of the genome that control health and disease.
We analyse single native molecules of DNA, RNA and protein to bring new insights across important emerging areas of biology. 
Senior Team
Gordon Hamilton MA MBBS MBA
Gordon is the CEO of Depixus. He brings experience of translational research and bioscience commercialization having worked as Medical Director for ChemoCentryx, a successful Silicon Valley biopharmaceutical company. He has previously also founded and built-up The Electives Network Ltd, an international medical education company. He has a First Class Master’s degree in Physiological Sciences from the University of Oxford, a medical degree from Imperial College School of Medicine, and an MBA from INSEAD.
Jimmy Ouellet PhD
Jimmy leads Depixus’ molecular biology activities. He has more than 15 years of research experience in areas spanning molecular biology, cell biology, oncology, and live microscopy. Jimmy has a PhD in biology from McGill University (Montréal, Canada) and did his post-doctoral training at the Swiss Federal Institute of Technology (ETH, Zürich Switzerland). Before joining Depixus in early 2015, he worked in the “Laboratoire de Physique Statistique” (LPS) of École Normale Supérieure in Paris. Here he was a member of the research group of Vincent Croquette, David Bensimon, and Jean-Francois Allemand, Depixus’ academic founders.
Pol d’Avezac PhD
Pol has been leading the data science effort for Depixus since joining the company in April 2016. He holds an engineering degree and a Ph.D. in particle physics from the Ecole Polytechnique. Since then, he has worked as a data scientist and R&D computer engineer, acquiring experience within both startups and multinational companies, in fields ranging from heavy process industries to medical instrumentation and geophysics.
Thibault Vieille PhD
Carl Glasse
Board Members
John Berriman
John Berriman is the Chairman of ReNeuron Group plc (listed on AIM) and Autifony Therapeutics Ltd; and past Chairman of Heptares Therapeutics Ltd (sold to Sosei in February 2015) and Algeta ASA (listed on the Oslo stock exchange and sold to Bayer AG in March 2014). He is also a non-executive director of Autolus Ltd. Until its sale to Amgen in the spring of 2012 he was a director of Micromet Inc. (listed on NASDAQ). Previously he was a director of Cytos AG (listed on the SIX Swiss exchange) and Abingworth Management, an international healthcare venture capital firm, where he was involved in founding, financing and serving as a director of several biotechnology companies in Europe and the USA – many of which obtained listings on public stock exchanges. Prior to that, he spent 14 years with Celltech Group plc and was a member of its Board when it listed on the London Stock Exchange in 1994. He has a degree in Chemical Engineering from the University of Cambridge and a Masters degree from the London Business School. In addition to the positions mentioned above, he was a founder and the first chairman of Solexa Ltd (now owned by Illumina Inc) the company which developed the DNA sequencing technology which is the dominant method of gene sequencing today.
Ronald Lindsay
Dr Ronald Lindsay is currently the Chief Executive Officer of Zebra Biologics, Inc., a company developing a disruptive new antibody generating platform. He previously served as Executive Vice President of Strategic Planning at Sequenom Inc, a company that pioneered the use of next generation sequencing for non-invasive prenatal diagnostics. Prior to Sequenom, Dr Lindsay held a variety of senior biopharmaceutical positions, directing discovery and preclinical research efforts in cancer, neuroscience, and genomics. He has served as Vice President, Research and Development, and Chief Science Officer of diaDexus, Inc; has been a Senior Advisor at the German venture capital fund TVM Capital GmbH; was a Member of the Scientific Advisory Board of Merck Serono S.A, has held various senior management roles with Millennium Pharmaceuticals, Inc; and was a co-founder of Regeneron Pharmaceuticals, Inc., today a pharmaceutical company with a market capitalisation of ~$40bn. He began his industry career as Head of Cell Biology at the Sandoz Institute for Medical Research, University College in London. He has authored over 150 scientific articles and was recognized by the Institute for Scientific Information as one of the most highly cited neuroscientists of the 1990's. He is also the holder of multiple patents. He has Ph.D. in Biochemistry from the University of Calgary and a B.Sc. (Honours) in Chemistry from the University of Glasgow.
Steve Allen PhD
Steve Allen has enjoyed a 30-year career with a track record of building a wide range of Life Science product and service companies, from start-ups to multinational corporations. Before his most recent role as CEO of DNAe, Steve held a number of leadership positions at PerkinElmer, Mettler-Toledo and LGC Forensics. Having led the acquisition of over 15 companies and the successful launch of more than fifty new scientific products and services, Steve has used his experience to assist early stage companies to make the step change from scientific innovation to commercial success. This includes the Next Generation Sequencing pioneer Solexa, where he was a Non-Executive Director and consultant, helping to scale the company to product launch and sale to Illumina. Steve has a PhD in Chemistry from the University of Nottingham.
Tim Xu
Tim joined Arix Bioscience in September 2019. He was previously an Engagement Manager at McKinsey & Company, where he advised pharmaceutical, insurance, and hospital clients on strategy and operations challenges. He has an MD from the Johns Hopkins School of Medicine, an MPP from the University of Cambridge, and a BA in Neuroscience and Modern European Studies from Vanderbilt University. Tim is a Non-Executive Director at Depixus and Board Observer at STipe Therapeutics and Amplyx Pharmaceuticals, all Arix portfolio companies. He is also a co-founder of Cogentis Therapeutics (Alzheimer’s disease) and Goldwater Scholar for his genetics translational research (obsessive-compulsive disorder). He has over 30 publications on US health policy, including as lead author in JAMA, JAMA Internal Medicine, and JAMA Surgery.
Lachlan MacKinnon
Lachlan joined Oxford Sciences Innovation in 2015 as a member of the founding team. Whilst there, he made investments at the intersection of technology and biology including foundational seed investments in OMass Therapeutics, ONI, Spybiotech, Nucleome and Base Genomics which was acquired by Exact Sciences in 2020 for $410m. In 2020 he left to found his own company and joined the board of Depixus as part of the Series A.
Investors
Early-stage investors
Depixus has strong backing from experienced early-stage investors, several of whom are veterans of the sequencing industry.
Other
We are also supported financially via a variety of grants and awards.
Venture Capital
Depixus is also backed by Arix Bioscience Limited, a global venture capital company focussed on investing in and building breakthrough biotechnology companies around cutting-edge advances in the life sciences. 